| Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of … D Cunningham, EA Hawkes, A Jack, W Qian, P Smith, P Mouncey, ... The Lancet 381 (9880), 1817-1826, 2013 | 642 | 2013 |
| Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi F Merli, S Luminari, A Tucci, A Arcari, L Rigacci, E Hawkes, CS Chiattone, ... Journal of clinical oncology 39 (11), 1214-1222, 2021 | 98 | 2021 |
| A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer F Sclafani, TY Kim, D Cunningham, TW Kim, J Tabernero, HJ Schmoll, ... Journal of the National Cancer Institute 107 (12), djv258, 2015 | 85 | 2015 |
| Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial M Gleeson, N Counsell, D Cunningham, N Chadwick, A Lawrie, ... Annals of Oncology 28 (10), 2511-2516, 2017 | 83 | 2017 |
| Programmed cell death-1 inhibition in lymphoma EA Hawkes, A Grigg, G Chong The Lancet Oncology 16 (5), e234-e245, 2015 | 83 | 2015 |
| Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: are we contributing to malignancy? E Newnham, E Hawkes, A Surender, SL James, R Gearry, PR Gibson Alimentary pharmacology & therapeutics 26 (7), 1019-1024, 2007 | 80 | 2007 |
| Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI JC Wight, G Chong, AP Grigg, EA Hawkes Blood reviews 32 (5), 400-415, 2018 | 76 | 2018 |
| Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer U Asghar, E Hawkes, D Cunningham Clinical colorectal cancer 9 (5), 274-281, 2010 | 76 | 2010 |
| EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity MK Gandhi, T Hoang, SC Law, S Brosda, K O’Rourke, JWD Tobin, F Vari, ... Blood, The Journal of the American Society of Hematology 137 (11), 1468-1477, 2021 | 74 | 2021 |
| CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial M Gleeson, C Peckitt, YM To, L Edwards, J Oates, A Wotherspoon, ... The Lancet Haematology 5 (5), e190-e200, 2018 | 71 | 2018 |
| The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma S Opat, A Tedeschi, K Linton, P McKay, B Hu, H Chan, J Jin, ... Clinical Cancer Research 27 (23), 6323-6332, 2021 | 64 | 2021 |
| Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma G Lenz, E Hawkes, G Verhoef, C Haioun, S Thye Lim, D Seog Heo, ... Leukemia 34 (8), 2184-2197, 2020 | 56 | 2020 |
| Novel indications for Bruton’s tyrosine kinase inhibitors, beyond hematological malignancies R Campbell, G Chong, EA Hawkes Journal of clinical medicine 7 (4), 62, 2018 | 54 | 2018 |
| Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks? S Barton, EA Hawkes, A Wotherspoon, D Cunningham The oncologist 17 (12), 1562-1573, 2012 | 51 | 2012 |
| Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular … A Kühnl, D Cunningham, N Counsell, EA Hawkes, W Qian, P Smith, ... Annals of Oncology 28 (7), 1540-1546, 2017 | 49 | 2017 |
| Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐CHOP) in the management of primary mediastinal B‐cell lymphoma: a subgroup analysis of the UK NCRI R … M Gleeson, EA Hawkes, D Cunningham, N Chadwick, N Counsell, ... British journal of haematology 175 (4), 668-672, 2016 | 46 | 2016 |
| Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer E Hawkes, AFC Okines, D Papamichael, S Rao, S Ashley, ... European Journal of Cancer 47 (8), 1146-1151, 2011 | 46 | 2011 |
| Cardiotoxicity in patients treated with bevacizumab is potentially reversible EA Hawkes, AFC Okines, C Plummer, D Cunningham Journal of Clinical Oncology 29 (18), e560-e562, 2011 | 43 | 2011 |
| Pembrolizumab in relapsed or refractory Richter syndrome P Armand, N Murawski, D Molin, J Zain, B Eichhorst, Z Gulbas, ... British journal of haematology 190 (2), e117-e120, 2020 | 37 | 2020 |
| Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience KL Lewis, CK Chin, K Manos, J Casey, N Hamad, J Crawford, SJ Ho, ... British journal of haematology 192 (6), 1049-1053, 2021 | 34 | 2021 |
